The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.

Back to full list of clinical trials

Ongoing clinical trials for hepatitis C: Actively recruiting


Condition:

HCV/HIV co-infection

Study title:

A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug boceprevir in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients

Basic eligibility criteria:

Adults coinfected with HCV genotype 1 and HIV

Principal Investigator:

Arthur Kim, MD

Contact:

Teri Flynn, RN, MSN, ANP; 617-726-5596


Condition:

Hepatitis C

Study title:

A Phase II Randomized, Double-blind, Placebo Controlled Study of the Clinical Effectiveness of a Human Monoclonal Antibody against Hepatitis C Virus E2 Glycoprotein (MBL-HCV1) in Hepatitis C Infected Patients Undergoing Liver Transplantation

Description of study:

This is a multicenter study evaluating the effectiveness of a new monoclonal antibody to HCV Genotype 1a in patients undergoing liver transplantation.  Study involves receiving infusion of study drug/placebo pre-op, intra-op and post-op daily for 7 days, followed by a post-op day 14 dose and 8 weeks of follow-up.

Basic eligibility criteria:

Eligible patients will be HCV genotype 1a undergoing cadaveric or living related OLT

Principal Investigator:

Ray Chung, MD

Contact:

Jenna Gustafson; 617-724-3836


Ongoing clinical trials for hepatitis C: No longer recruiting


Study title:

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS-5885 Alone or in Combination with GS-9451 or GS-9256 with Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1 Hepatitis C Virus Infection

Description of study:

This study is providing two investigational drugs in combination with Peginterferon and Ribavirin to adult subjects to evaluate its safety, efficacy and tolerability in treating chronic HCV infection.

Principal Investigator:

Ray Chung, MD


Study title:

A Phase 3, Multicenter, Randomized, Active-Controlled, Study to Investigate Safety and Efficacy of PSI-7977 and Ribavirin for 12 Weeks Compared to Pegylated Interferon and Ribavirin for 24 Weeks in Treatment-Naïve Patients with Chronic Genotype 2 or 3 HCV Infection

Description of study:

This study is evaluating the safety and effectiveness of PSI-7977 + Ribavirin compared to Peginterferon + Ribavirin in adults with HCV genotype 2 or 3.

Principal Investigator:

Ray Chung, MD


Study title:

An Open-Label Study to Explore the Clinical Efficacy of PSI-7977 with Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Description of study:

This study is evaluating the effectiveness of PSI-7977 + Ribavirin in treating HCV pre-transplant and preventing HCV recurrence post-transplant.

Principal Investigator:

Ray Chung, MD


Study title:

Open Label Study of Safety and Efficacy with BMS-790052 plus PEG/RBV in Previously Untreated HCV Patients Co-infected with HIV and HCV

Description of study:

This study will evaluate the safety, efficacy and tolerability of the drug BMS-790052 in combination with Peginterferon and Ribavirin for the treatment of HCV in co-infected patients.

Principal Investigator:

Arthur Kim, MD